IL272418B2 - Abinotuzumab treatment of a new subgroup of DLBCL patients - Google Patents

Abinotuzumab treatment of a new subgroup of DLBCL patients

Info

Publication number
IL272418B2
IL272418B2 IL272418A IL27241820A IL272418B2 IL 272418 B2 IL272418 B2 IL 272418B2 IL 272418 A IL272418 A IL 272418A IL 27241820 A IL27241820 A IL 27241820A IL 272418 B2 IL272418 B2 IL 272418B2
Authority
IL
Israel
Prior art keywords
patient
antibody
dlbcl
chop
patients
Prior art date
Application number
IL272418A
Other languages
English (en)
Hebrew (he)
Other versions
IL272418B1 (en
IL272418A (en
Original Assignee
Hoffmann La Roche
Nanostring Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Nanostring Technologies Inc filed Critical Hoffmann La Roche
Publication of IL272418A publication Critical patent/IL272418A/en
Publication of IL272418B1 publication Critical patent/IL272418B1/en
Publication of IL272418B2 publication Critical patent/IL272418B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL272418A 2017-08-08 2018-08-08 Abinotuzumab treatment of a new subgroup of DLBCL patients IL272418B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762542489P 2017-08-08 2017-08-08
PCT/EP2018/071462 WO2019030260A1 (en) 2017-08-08 2018-08-08 OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP

Publications (3)

Publication Number Publication Date
IL272418A IL272418A (en) 2020-03-31
IL272418B1 IL272418B1 (en) 2024-05-01
IL272418B2 true IL272418B2 (en) 2024-09-01

Family

ID=63209389

Family Applications (1)

Application Number Title Priority Date Filing Date
IL272418A IL272418B2 (en) 2017-08-08 2018-08-08 Abinotuzumab treatment of a new subgroup of DLBCL patients

Country Status (20)

Country Link
US (2) US11597772B2 (OSRAM)
EP (1) EP3665196B1 (OSRAM)
JP (2) JP7418322B2 (OSRAM)
KR (1) KR102799421B1 (OSRAM)
CN (2) CN119798437A (OSRAM)
AU (1) AU2018314765C1 (OSRAM)
CA (1) CA3071618A1 (OSRAM)
CR (1) CR20200061A (OSRAM)
ES (1) ES2933256T3 (OSRAM)
IL (1) IL272418B2 (OSRAM)
MA (1) MA49830A (OSRAM)
MX (1) MX2020001493A (OSRAM)
MY (1) MY202382A (OSRAM)
PE (1) PE20200738A1 (OSRAM)
PL (1) PL3665196T3 (OSRAM)
SG (1) SG11202000985XA (OSRAM)
TW (1) TWI772488B (OSRAM)
UA (1) UA126204C2 (OSRAM)
WO (1) WO2019030260A1 (OSRAM)
ZA (1) ZA202000680B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
TWI772488B (zh) 2017-08-08 2022-08-01 瑞士商赫孚孟拉羅股份公司 新穎DLBCL病患次族群之歐比托珠單抗(obinutuzumab)治療
GB2596411B (en) * 2018-10-29 2023-09-20 Tigatx Inc Compositions and methods comprising IgA antibody constructs
CA3127113A1 (en) 2019-01-30 2020-08-06 Dongxu Sun Anti-gal3 antibodies and uses thereof
AU2021278935A1 (en) 2020-05-26 2022-12-08 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3752017T2 (de) 1986-03-20 1997-08-28 Nippon Electric Co Mikrorechner mit Zugriffsfähigkeit auf einen internen Speicher mit gewünschter variabler Zugriffszeit
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
RS55723B1 (sr) 2003-11-05 2017-07-31 Roche Glycart Ag Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
GB0718684D0 (en) * 2007-09-24 2007-10-31 Roche Products Ltd Treatment method
US20130195843A1 (en) * 2010-06-23 2013-08-01 British Columbia Cancer Agency Branch Biomarkers for Non-Hodgkin Lymphomas and Uses Thereof
KR102357699B1 (ko) * 2013-11-06 2022-02-04 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 발현 프로파일링에 의한 림프종 유형의 하위유형 분류 방법
DE102013222576A1 (de) 2013-11-06 2015-05-07 BSH Bosch und Siemens Hausgeräte GmbH Haushaltsgerät
CN114632158A (zh) 2013-11-07 2022-06-17 豪夫迈·罗氏有限公司 抗cd20抗体与btk抑制剂的组合疗法
CA2943329A1 (en) * 2014-03-24 2015-10-01 Genentech, Inc. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
RU2704611C2 (ru) * 2014-09-15 2019-10-30 Дженентек, Инк. Составы на основе антител
EP3689910A3 (en) * 2014-09-23 2020-12-02 F. Hoffmann-La Roche AG Method of using anti-cd79b immunoconjugates
MX392539B (es) * 2015-06-08 2025-03-24 Debiopharm Int Sa Combinaciones de inmunoconjugado anti-cd37 y anticuerpo anti-cd20.
CR20170537A (es) 2015-06-24 2018-02-20 Hoffmann La Roche Anticuerpos contra csf-1r humano para uso en la inducción de linfocitosis en linfomas o leucemias.
ES2901794T3 (es) * 2015-12-09 2022-03-23 Hoffmann La Roche Anticuerpo anti-CD20 de tipo II para reducir la formación de anticuerpos antifármaco
EP3178848A1 (en) * 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
TWI772488B (zh) 2017-08-08 2022-08-01 瑞士商赫孚孟拉羅股份公司 新穎DLBCL病患次族群之歐比托珠單抗(obinutuzumab)治療

Also Published As

Publication number Publication date
TWI772488B (zh) 2022-08-01
CR20200061A (es) 2020-05-23
AU2018314765A1 (en) 2020-01-30
PE20200738A1 (es) 2020-07-23
WO2019030260A1 (en) 2019-02-14
CA3071618A1 (en) 2019-02-14
JP2020530002A (ja) 2020-10-15
PL3665196T3 (pl) 2023-01-23
CN119798437A (zh) 2025-04-11
IL272418B1 (en) 2024-05-01
EP3665196B1 (en) 2022-10-19
JP2023179425A (ja) 2023-12-19
CN111032692A (zh) 2020-04-17
AU2018314765C1 (en) 2025-11-20
MX2020001493A (es) 2020-03-24
ES2933256T3 (es) 2023-02-03
NZ761111A (en) 2024-05-31
TW201910353A (zh) 2019-03-16
TW202323297A (zh) 2023-06-16
US20200317800A1 (en) 2020-10-08
US20230348611A1 (en) 2023-11-02
US11597772B2 (en) 2023-03-07
UA126204C2 (uk) 2022-08-31
IL272418A (en) 2020-03-31
KR102799421B1 (ko) 2025-04-30
AU2018314765B2 (en) 2025-03-20
ZA202000680B (en) 2024-09-25
KR20200035441A (ko) 2020-04-03
SG11202000985XA (en) 2020-02-27
EP3665196A1 (en) 2020-06-17
MA49830A (fr) 2021-03-31
JP7418322B2 (ja) 2024-01-19
MY202382A (en) 2024-04-24

Similar Documents

Publication Publication Date Title
US20230348611A1 (en) Obinutuzumab treatment of a dlbcl patient subgroup
US20230295302A1 (en) Methods of treating tumor
US20240018242A1 (en) Methods of treating cancer using lsd1 inhibitors in combination with immunotherapy
EP1981539B1 (en) Treatment of metastatic breast cancer
US20250134996A1 (en) Treatment of hodgkin lymphoma using an anti-pd-1 antibody
JP2015508156A (ja) バイオマーカーならびに腫瘍溶解性ウイルスと免疫調節法とを用いる併用療法
KR20190139225A (ko) 암 치료제용 생물마커
CN113396230A (zh) 癌症的诊断和治疗方法
TWI909088B (zh) 新穎DLBCL病患次族群之歐比托珠單抗（obinutuzumab）治療
HK40027710A (en) Obinutuzumab treatment of a dlbcl patient subgroup
HK40098571A (en) Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma
HK40055955A (en) Diagnostic and therapeutic methods for cancer
HK1123987A (en) Treatment of metastatic breast cancer
HK1123987B (en) Treatment of metastatic breast cancer